32.48
32.48 (0%)
As of Apr 01, 2024
Cymabay Therapeutics, Inc. [CBAY]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
| Country | United States |
| Headquarters | fremont, california |
| Phone Number | (510) 293-8800 |
| Industry | manufacturing |
| CEO | Sujal Shah |
| Website | www.cymabay.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $31.1 |
| Operating Profit | $-101.7 |
| Net Income | $-105.4 |
| Net Cash | $186.7 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -327.2 |
| Profit as % of Revenues | |
| Profit as % of Assets | -36.6% |
| Profit as % of Stockholder Equity | -36.1% |
Management Effectiveness
| Return on Equity | -36.1% |
| Return on Assets | -24.2% |
| Turnover Ratio | 0.1% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $434.7 |
| Total Liabilities | $142.4 |
| Operating Cash Flow | $-72.5 |
| Investing Cash Flow | $-86.6 |
| Financing Cash Flow | $345.8 |
